Open AccessArticle Erythrocyte and Platelet Indices at Admission and Discharge Stratify Long-Term Cardiovascular Risk After Invasive Treatment of Myocardial Infarction Christoph Strohhofer Christoph Strohhofer 1,*, Faisal Aziz Faisal Aziz 2, Andreas Kainz Andreas Kainz 3, Andrea Berghold Andrea Berghold 3, Nicolas Verheyen Nicolas Verheyen 1, Heiko Bugger Heiko Bugger 1, Stefan Hatzl Stefan Hatzl 4,5, Raffaela Planka Raffaela Planka 1, Friederike von Lewinski Friederike von Lewinski 6, Johannes Gollmer Johannes Gollmer 1, Klemens Ablasser Klemens Ablasser 1, Ivan Vosko Ivan Vosko 1, Michael Sacherer Michael Sacherer 1, Gabor G. Toth Gabor G. Toth Dr. Gabor G. Toth is currently a staff-member Interventional Cardiologist at the University Graz, He [...] Read more 1, Ewald Kolesnik Ewald Kolesnik 1, Andreas Zirlik Andreas Zirlik Dr. Andreas Zirlik is a University Professor of Cardiology and Head of the Department of Cardiology, [...] Read more 1, Harald Sourij Harald Sourij Harald Sourij graduated sub auspiciis presidentis rei publicae 2004 from the Medical University of a [...] Read more 2 Dirk von Lewinski Dirk von Lewinski 1 1 Division of Cardiology, Department of Internal Medicine, Medical University of Graz, 8010 Graz, Austria 2 Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, 8010 Graz, Austria 3 Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, 8010 Graz, Austria 4 Division of Hematology, Department of Internal Medicine, Medical University of Graz, 8010 Graz, Austria 5 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA 6 Interdisciplinary Metabolic Medicine Trials Unit, Medical University of Graz, 8010 Graz, Austria * Author to whom correspondence should be addressed. J. Clin. Med. 2026, 15(12), 4455; https://doi.org/10.3390/jcm15124455 (registering DOI) Submission received: 24 April 2026 / Revised: 5 June 2026 / Accepted: 7 June 2026 / Published: 9 June 2026 Abstract Background/Objectives: Cardiovascular risk remains substantial after myocardial infarction (MI) despite established clinical risk markers. Erythrocyte and platelet indices are routinely available, but their long-term prognostic relevance remains insufficiently studied. Methods: This retrospective cohort study was based on the Styrian Registry on Genuine Myocardial Infarction (STRONG-MI) and included patients with MI undergoing invasive coronary angiography in Styria, Austria, between January 2007 and March 2016. Multivariable Cox regression models were used to assess the associations of admission and discharge erythrocyte and platelet indices with 3-point major adverse cardiovascular events (MACE) during follow-up extending to 175 months. Results: Among 10,920 patients, admission hemoglobin showed a U-shaped association with MACE. Median hemoglobin decreased from admission to discharge (14.2 g/dL vs. 13.1 g/dL) and the lowest discharge tertile showed the highest association with MACE compared with the middle tertile (AHR 1.27, 95% CI 1.18–1.38). Lower mean corpuscular hemoglobin concentration (MCHC) was independently linked to adverse outcomes at both admission and discharge (AHR 1.17, 95% CI 1.08–1.27, and 1.14, 95% CI 1.05–1.23, respectively). Higher platelet count and mean platelet volume (MPV) were also associated with increased risk, particularly at discharge (AHR 1.15, 95% CI 1.06–1.24, and 1.19, 95% CI 1.10–1.29, respectively). Conclusions: Routine erythrocyte and platelet indices were independently associated with long-term cardiovascular outcomes after invasively treated MI and reflect residual biological risk after discharge. Keywords: myocardial infarction; acute coronary syndrome; hemoglobin; red blood cell indices; platelets; prognostic biomarkers 1. Introduction Beyond hemoglobin, the prognostic significance of other routine erythrocyte indices, including mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC), is less well established. These indices reflect erythrocyte morphology and hemoglobinization and may provide information beyond hemoglobin alone. Prior studies have reported associations between erythrocyte indices and adverse outcomes after MI, but findings have been inconsistent and were often derived from selected populations or shorter follow-up [ 17, 18]. 2. Materials and Methods 2.1. Study Design and Population The Styrian Registry on Genuine Myocardial Infarction (STRONG-MI) systematically includes all patients with myocardial infarctions who were referred for coronary angiography in Styria, Austria, between January 2007 and March 2016. To ensure comprehensive regional coverage, data from all three interventional cardiology centers in Styria were included: University Hospital Graz; LKH Graz II, West location; and LKH Hochsteiermark, Location Bruck an der Mur. These centers represent the only facilities performing acute invasive coronary procedures in a region of approximately 1,200,000 inhabitants. The classification of MI subtypes for inclusion into the registry was based on clinical presentation, ECG findings, and biomarker assessment. ST-elevation myocardial infarction (STEMI) was defined by acute chest pain (or equivalent symptoms) and persistent ST-segment elevation (or its equivalents) on ECG, fulfilling the universal definition of MI at that time [ 22]. Patients with acute chest pain but without persistent ST-segment elevation were further categorized based on high-sensitivity cardiac troponin (hs-cTn) levels. NSTEMI was diagnosed if hs-cTn levels showed a significant rise and/or fall above the 99th percentile, indicating myocardial necrosis. All patients included in the STRONG-MI registry were analyzed, irrespective of whether both admission and discharge hemogram values were available. Missing discharge hemogram values were handled within the multiple imputation framework. The study was conducted under the approval by the Ethics Committee of the Medical University of Graz (EK No: 28-433 ex15/16, 1200/2016) for the parent registry, and data were collected in accordance with ethical and regulatory guidelines. 2.2. Follow-Up and Study Endpoints Time-to-event follow-up began at the date of coronary angiography during the index hospitalization and continued until the first occurrence of the outcome of interest or administrative censoring at the last available date of outcome follow-up. Follow-up events were identified through ICD-coded diagnoses from the regional hospital information system (HIS) openMEDOCS. Mortality data were obtained from Statistics Austria, the official national source for mortality statistics in Austria. Cause of death was based on official death certificates completed by the responsible examining physicians and was used to classify cardiovascular and non-cardiovascular mortality according to ICD-10 codes. The 3-point MACE endpoint was defined as cardiovascular mortality (ICD-10 codes I00–I78), recurrent MI (ICD-10 codes I21.0–I21.4, I21.9), and stroke (ICD-10 codes I61, I63, I64). The data were extracted by the Institute for Medical Informatics, Statistics and Documentation of the Medical University of Graz and provided in accordance with data protection laws on internal servers. To improve endpoint validity and avoid double counting of recurrent MI across hospitals due to interhospital transfers or rehabilitation stays, all recurrent MI diagnoses not confirmed by inclusion in the STRONG-MI registry were individually reviewed and adjudicated by the first author, a clinician in internal medicine and cardiology. This review was based on ICD-coded diagnoses from openMEDOCS and available clinical information, including timing of diagnosis, ECG findings and biomarker assessment. 2.3. Laboratory Variables Laboratory data were collected as part of routine clinical care during the index hospitalization. Therefore, admission values were generally obtained during the acute presentation, whereas discharge values were drawn according to clinical need, often shortly before discharge but without a standardized protocol. The first available measurement was defined as the admission value, and the last available measurement as the discharge value. The term discharge value was used operationally and refers to the last available in-hospital hemogram measurement, including patients without a formal discharge record. The present analysis focused on erythrocyte and platelet indices derived from the routine blood count, including hemoglobin, erythrocyte count, hematocrit, MCH, MCHC, MCV, platelet count, and MPV. Because identical reference ranges were used across hospitals within the Styrian Hospital Association, data could be merged across centers. Parameters primarily reflecting systemic inflammation, such as white blood cell count, were not included because they represent a distinct biological domain from erythrocyte and platelet indices. 2.4. Statistical Analysis Statistical analyses were performed using R version 4.4.2. Data are reported as frequency and percentage (%) for categorical variables and mean ± standard deviation (SD) or median and interquartile range (IQR) for continuous variables. Comparisons according to MACE status were performed using the chi-square test for categorical variables and the Wilcoxon rank-sum test for continuous variables. The incidence probabilities were estimated using Kaplan–Meier curves, and log-rank tests were applied to compare probability curves by hemogram tertiles. Incidence rates and cumulative incidence of composite and individual MACE with respect to hemogram tertiles were calculated at prespecified time points. Cox proportional-hazards regression models were used to ascertain the association of tertile-based hematological variables with the risk of composite and individual MACE. The proportional hazards assumption was assessed using Schoenfeld residuals. Fine-Gray competing-risk models were used as sensitivity analyses for recurrent MI and stroke, treating all-cause death before the respective non-fatal event as the competing event. Univariable models were used to estimate unadjusted associations of each hematological variable with MACE. In multivariable Cox regression, the association of hematological variables with MACE was adjusted for age, sex, BMI, hyperlipidemia, MI type, previous MI, previous stroke, diabetes, multiple- versus single-vessel PCI, number of baseline comorbidities, and eGFR. To explore the incremental discriminatory value of hematological indices, additional time-dependent receiver operating characteristic (ROC) analyses were performed. The clinical base model included age, sex, BMI, hyperlipidemia, MI type, previous MI, previous stroke, diabetes, multiple- versus single-vessel PCI, number of baseline comorbidities, and eGFR. The number of baseline comorbidities was defined as an unweighted count of ICD-10-coded hypertension, hyperlipidemia, diabetes mellitus, chronic obstructive pulmonary disease, atrial fibrillation or flutter, and asthma documented in openMEDOCS. Extended models additionally included one selected hematological marker at a time. Exploratory model discrimination was assessed using time-dependent area under the curve (AUC) at 60 and 120 months. Given the exploratory nature of these analyses, ROC/AUC results were used to describe potential incremental discrimination and were not intended to develop or validate a clinical prediction model. Missing data were managed using multivariate imputation with the multivariate imputation by chained equations (MICE) package in R. Imputations were performed separately for admission and discharge hemogram measurements. The imputation models included demographic and clinical variables, hemogram variables (missing and non-missing), and outcome variables. The Nelson-Aalen cumulative hazard estimator was used as an auxiliary predictor in the imputation models to account for the time-to-event structure of outcomes. Variables were imputed using predictive mean matching (PMM). For each imputation model, 40 imputed datasets were generated using 20 iterations. Convergence was assessed using trace plots, and plausibility of imputations was assessed using density plots. Subsequent analyses were performed across the imputed datasets according to Rubin’s rules. To assess robustness, complete-case sensitivity analyses were reported for the multivariable Cox models. Because the evaluated hematological indices are biologically interrelated, the primary interpretation was based on coherent patterns across related parameters rather than on isolated p-values. Given the number of markers, Benjamini–Hochberg false-discovery-rate adjustment was additionally applied to the main tertile-based MACE analyses as a sensitivity assessment, and both nominal and FDR-adjusted p-values are reported. 3. Results The study included 10,920 patients with MI ( Table 1). NSTEMI was more frequent than STEMI (62% vs. 38%). Most patients were male (65%; n = 7116), the mean age was 66.6 ± 12.7 years, and median body mass index (BMI) was 27.0 kg/m 2 (IQR 24.4–30.0). Hypertension (72%; n = 7889) and hyperlipidemia (44%; n = 4825) were the most prevalent cardiovascular risk factors, followed by diabetes mellitus in 25% (n = 2712). Chronic obstructive pulmonary disease was present in 8.7% (n = 945), and asthma in 1.3% (n = 140). Median estimated glomerular filtration rate (CKD-EPIBSA) was 73.8 mL/min/1.73 m 2 (IQR 54.2–89.7). The median length of hospital stay was 8 days (IQR 5–13). At admission, median hemoglobin was 14.2 g/dL (IQR 13.0–15.3), median erythrocyte count was 4.6 million/µL (IQR 4.3–5.0), and median hematocrit was 41.5% (IQR 38.3–44.2). Median MCV was 89.0 fL (86.2–92.1), MCH was 30.5 pg/cell (IQR 29.3–31.7) and MCHC was 34.0 g/dL (IQR 33.3–35.0). Median MPV at admission was 10.0 fL (IQR 9.0–10.8). At discharge, median hemoglobin decreased to 13.1 g/dL (IQR 11.7–14.3) and erythrocyte count to 4.32 million/µL (IQR 3.9–4.7), whereas platelet count remained largely stable, increasing slightly from 228.0 × 10 9/L (IQR 190.0, 273.0) to 234.0 × 10 9/L (IQR 190.0, 296.0). Median MPV was 10.1 fL (IQR 9.1–11.0) at discharge. Tertile cutoffs for all hematological indices are shown in Table S1. To facilitate interpretation of the main findings, hemoglobin tertiles were approximately 15.3 g/dL at admission and 14.3 g/dL at discharge. Corresponding MPV tertiles were 10.8 fL at admission and 11.0 fL at discharge. The cumulative incidence of 3-point MACE was 12.3% at 1 year and 24% at 5 years. At 1 year, cumulative incidences were 4.3% for recurrent MI and 1.4% for stroke, while all-cause and cardiovascular mortality were 10.5% and 7.3%, respectively. During the overall follow-up of 103 months (IQR 69–138), extending to 175 months, 31.5% of patients experienced a 3-point MACE ( Table S2). All-cause mortality occurred in 36% of the cohort and cardiovascular mortality in 18%, whereas non-fatal recurrent MI and non-fatal stroke were observed in 11.5% and 7%, respectively. In multivariable Cox regression analyses adjusted for age, sex, BMI, hyperlipidemia, MI type, prior MI, prior stroke, diabetes, multiple- versus single-vessel PCI, number of baseline comorbidities, and eGFR, admission and discharge hematological indices showed distinct associations with 3-point MACE ( Table 2). Assessment based on Schoenfeld residuals showed no relevant violation of the proportional hazard assumption for the main Cox models. At admission, hemoglobin showed a clear U-shaped relationship with 3-point MACE ( Figure 2). Compared with the middle tertile, both the lowest and highest tertiles carried increased risk (AHR 1.19, 95% CI 1.09–1.29 and AHR 1.11, 95% CI 1.02–1.22, respectively). In addition, lower hematocrit, erythrocyte count, MCH, and MCHC were associated with higher risk, whereas MCV showed no relationship with 3-point MACE. At discharge, erythrocyte-related associations were stronger and more consistent ( Figure S3). Lower hemoglobin, erythrocyte count, hematocrit, and MCHC all identified patients at higher risk of 3-point MACE. The strongest risks were observed for low hemoglobin (AHR 1.27, 95% CI 1.18–1.38) and low erythrocyte count (AHR 1.24, 95% CI 1.14–1.34). MCV again showed no association. In contrast, platelet-related associations were concentrated in the upper tertiles. Higher platelet count was associated with increased risk at both admission and discharge when analyzed by tertiles (admission high tertile: AHR 1.11, 95% CI 1.02–1.21; discharge high tertile: AHR 1.15, 95% CI 1.06–1.24). Similarly, MPV was linked to an increased risk in the highest tertile at admission (AHR 1.09, 95% CI 1.01–1.18) and at discharge (AHR 1.19, 95% CI 1.10–1.29). Missingness was low across covariates and hematological variables ( Table S3). Complete-case sensitivity analyses yielded consistent results with the imputed main analyses and are presented in Table S4. In Fine-Gray competing-risk sensitivity analyses for recurrent MI and stroke, with all-cause death treated as the competing event, the endpoint-specific associations were broadly consistent with the main analyses and did not materially alter the interpretation of the findings ( Figure S4). In exploratory time-dependent ROC analyses, the clinical base model discriminated 3-point MACE at 60 and 120 months with AUC values of 0.708 (95% CI 0.697–0.721) and 0.707 (95% CI 0.695–0.719), respectively. Addition of individual hematological markers resulted in similar AUC values ( Figure S5) and did not significantly improve model discrimination compared with the clinical base model. 4. Discussion The U-shaped relationship between admission hemoglobin and long-term MACE is biologically plausible. Low hemoglobin may reflect reduced oxygen-carrying capacity, bleeding susceptibility, frailty, or malignant disease. Conversely, high hemoglobin may identify patients with smoking-related erythrocytosis, chronic hypoxemia, or other conditions linked to increased blood viscosity and vascular risk [ 23]. Admission values may capture chronic baseline status better, whereas discharge values may integrate the cumulative impact of infarct severity, procedural burden, bleeding, hemodilution, and repeated blood sampling during hospitalization, thereby potentially reflecting hospital-acquired anemia. Importantly, hemoglobin and erythrocyte indices may also be influenced by several additional underlying conditions, including iron deficiency, chronic inflammation, malignancy, liver disease, vitamin B12 or folate deficiency, and hematological disorders. Therefore, the observed associations should primarily be interpreted as markers of residual biological vulnerability rather than as direct evidence of causal effects of individual blood count parameters. Although 3-point MACE was chosen as the primary endpoint, the excess risk associated with low hemoglobin was driven predominantly by cardiovascular death. This is clinically important, because it suggests that low erythrocyte reserve after MI may be less a marker of isolated recurrent ischemic events than of broader cardiovascular fragility. The associations of MCHC may be of particular interest, as MCHC reflects erythrocyte hemoglobinization rather than cell size alone. Platelet-related findings followed a different but equally plausible pattern. Higher platelet count and MPV at both admission and discharge were linked to worse outcomes. This is consistent with the central role of platelet activation in recurrent atherothrombotic events. The stronger association of MPV at discharge may indicate persistent platelet activation beyond the acute phase. Several limitations must be acknowledged. First, the retrospective design precludes causal inference. Second, some clinically relevant variables, particularly smoking status and medication data, could not be extracted by the HIS in a standardized manner. Smoking may partly explain the increased risk observed at higher hemoglobin levels, for example through smoking-related erythrocytosis or chronic hypoxemia. Medication use, including antiplatelet therapy, anticoagulation, statins, beta-blockers, renin-angiotensin-system inhibitors, and P2Y12 inhibitor selection, may also have influenced long-term outcomes. However, because all patients underwent invasive management at dedicated PCI centers during an era of established guideline-based secondary prevention, most patients were expected to have received care broadly consistent with contemporary treatment. Generalizability to current practice may still be affected by evolving stent technology, antiplatelet strategies, and lipid-lowering therapy. Even if baseline smoking data were available for the entire cohort, it would still likely incompletely reflect long-term exposure after MI, as the index event often triggers smoking cessation. Nevertheless, residual confounding cannot be excluded. Markers that may help to further characterize the etiology of altered erythrocyte indices, such as iron studies or vitamin levels, were also not routinely available in sufficient completeness for robust analysis. Although repeated laboratory measurements were available during hospitalization, the present analysis focused on admission and discharge values rather than full in-hospital trajectories. This approach improves interpretability and clinical applicability, but it may not fully capture dynamic changes over time. Length of hospital stay was added to characterize the clinical interval between admission and discharge measurements. Nevertheless, variability in hospitalization duration and non-standardized timing of the last laboratory assessment may have influenced discharge-based analyses. Discharge hemogram parameters should therefore be interpreted as markers of later in-hospital clinical status associated with subsequent outcomes. Although several hematological indices were independently associated with long-term MACE, their addition to the clinical base model did not substantially improve time-dependent AUC. Therefore, the present study should not be interpreted as a formal prediction-model study. Overall, this study shows that routine erythrocyte and platelet indices are associated with complementary patterns of long-term cardiovascular risk after invasively treated MI. Notably, discharge erythrocyte indices yielded a more consistent risk signal than admission values, whereas platelet-related risk was consistently concentrated in the upper range. Our findings do not imply that correction of an abnormal laboratory value alone will improve prognosis [ 24, 25]. Rather, these parameters appear to function as accessible markers of underlying biological vulnerability after MI. Their universal availability and negligible cost make them attractive candidate markers for future risk models and for characterizing patients who may merit closer follow-up after hospital discharge. Supplementary Materials The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/jcm15124455/s1. Table S1: Hemogram values overall, by tertiles and outcome; Table S2: Overall outcomes and follow-up time; Table S3: Missing data summary; Table S4: Multivariable Cox regression analysis of MACE with hematological marker tertiles at admission and discharge (complete case analysis); Figure S1: Kaplan–Meier Curves for 3-point MACE Stratified by Discharge Tertiles; Figure S2: Kaplan–Meier estimates of event probability for cardiovascular death, recurrent myocardial infarction, and stroke; Figure S3: Adjusted hazard ratios of MACE for hemogram values at discharge; Figure S4: Adjusted hazard ratios for recurrent myocardial infarction and stroke according to hematological marker tertiles at admission and discharge; Figure S5: Time-dependent receiver operating characteristic curves for the clinical base model plus the respective admission hematological marker shown in each panel. Author Contributions C.S.: Conceptualization, Methodology, Formal analysis, Investigation, Data curation, Writing—original draft, Writing—review and editing; F.A.: Investigation, Formal analysis, Writing—review and editing; A.K.: Methodology, Formal analysis, Data curation, Writing—review and editing; A.B.: Methodology, Formal analysis, Writing—review and editing; N.V.: Investigation, Writing—review and editing; H.B.: Conceptualization, Investigation, Writing—review and editing; S.H., R.P., J.G., K.A., I.V., M.S., G.G.T. and E.K.: Investigation, Writing—review and editing; F.v.L.: Conceptualization, Writing—review and editing; A.Z.: Conceptualization, Writing—review and editing, Supervision; H.S.: Conceptualization, Methodology, Writing—review and editing, Supervision; D.v.L.: Conceptualization, Methodology, Validation, Investigation, Writing—review and editing, Supervision, Project administration. All authors have read and agreed to the published version of the manuscript. Funding This research received no external funding. Institutional Review Board Statement The study was conducted under the approval by the Ethics Committee of the Medical University of Graz (EK No: 28-433 ex15/16, 1200/2016; approval date: 25 May 2016) for the parent registry, and data were collected in accordance with ethical and regulatory guidelines. Informed Consent Statement Patient consent was waived by the Ethics Committee due to the retrospective nature of the study and the use of anonymized/de-identified routinely collected clinical data. Data Availability Statement Data will be shared on request to the corresponding author with permission of the Institute for Medical informatics, Statistics and Documentation of the Medical University of Graz. Acknowledgments The authors would like to thank all individuals and groups who have contributed to the development of this study. No additional acknowledgements are deemed necessary beyond those already included. As per ICMJE guidelines, each contributor’s role is specified within the manuscript. Conflicts of Interest The authors declare no conflicts of interest. References Filh, J.G.M.S. Hematological Parameters as Prognostic Biomarkers in Patients with Cardiovascular Diseases. Curr. Cardiol. Rev. 2019, 15, 274–282. [] [ CrossRef] Sigirci, S.; Ser, Ö.S.; Keskin, K.; Yildiz, S.S.; Gurdal, A.; Kilickesmez, K.O. Comparing the Prognostic Value of Hematological Indices in Patients with ST Segment Elevation Myocardial Infarction: “A Head to Head” Analysis. Angiology 2021, 72, 348–354. [] [ CrossRef] Babes, E.E.; Zaha, D.C.; Tit, D.M.; Nechifor, A.C.; Bungau, S.; Andronie-Cioara, F.L.; Behl, T.; Stoicescu, M.; Munteanu, M.A.; Rus, M.; et al. Value of Hematological and Coagulation Parameters as Prognostic Factors in Acute Coronary Syndromes. Diagnostics 2021, 11, 850. [] [ CrossRef] [ PubMed] Huynh, R.; Hyun, K.; D’Souza, M.; Kangaharan, N.; Shetty, P.C.; Mariani, J.; Kilian, J.; Hung, J.; Ryan, M.; Chew, D.P.; et al. Outcomes of Anemic Patients Presenting with Acute Coronary Syndrome: An Analysis of the Cooperative National Registry of Acute Coronary Care, Guideline Adherence and Clinical Events. Clin. Cardiol. 2019, 42, 791–796. [] [ CrossRef] Monteiro Júnior, J.G.d.M.; Torres, D.d.O.C.; da Silva, M.C.F.C.; Martins, C.M.d.H.; da Silva, I.K.; do Nascimento, M.E.M.; dos Santos, A.C.O.; Montarroyos, U.R.; Filho, D.C.S. Prognostic Value of Hematological Parameters in Patients with Acute Myocardial Infarction: Intrahospital Outcomes. PLoS ONE 2018, 13, e0194897. [] [ CrossRef] [ PubMed] Lawler, P.R.; Filion, K.B.; Dourian, T.; Atallah, R.; Garfinkle, M.; Eisenberg, M.J. Anemia and Mortality in Acute Coronary Syndromes: A Systematic Review and Meta-Analysis. Am. Heart J. 2013, 165, 143–153.e5. [] [ CrossRef] Liu, Y.; Yang, Y.M.; Zhu, J.; Tan, H.Q.; Liang, Y.; Li, J.D. Anaemia and Prognosis in Acute Coronary Syndromes: A Systematic Review and Meta-Analysis. J. Int. Med. Res. 2012, 40, 43–55. [] [ CrossRef] Kwok, C.S.; Tiong, D.; Pradhan, A.; Andreou, A.Y.; Nolan, J.; Bertrand, O.F.; Curzen, N.; Urban, P.; Myint, P.K.; Zaman, A.G.; et al. Meta-Analysis of the Prognostic Impact of Anemia in Patients Undergoing Percutaneous Coronary Intervention. Am. J. Cardiol. 2016, 118, 610–620. [] [ CrossRef] Guedeney, P.; Sorrentino, S.; Claessen, B.; Mehran, R. The Link between Anemia and Adverse Outcomes in Patients with Acute Coronary Syndrome. Expert Rev. Cardiovasc. Ther. 2019, 17, 151–159. [] [ CrossRef] Mamas, M.A.; Kwok, C.S.; Kontopantelis, E.; Fryer, A.A.; Buchan, I.; Bachmann, M.O.; Zaman, M.J.; Myint, P.K. Relationship Between Anemia and Mortality Outcomes in a National Acute Coronary Syndrome Cohort: Insights from the UK Myocardial Ischemia National Audit Project Registry. J. Am. Heart Assoc. 2016, 5, e003348. [] [ CrossRef] Wester, A.; Attar, R.; Mohammad, M.A.; Andell, P.; Hofmann, R.; Jensen, J.; Szummer, K.; Erlinge, D.; Koul, S. Impact of Baseline Anemia in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: A Prespecified Analysis from the VALIDATE-SWEDEHEART Trial. J. Am. Heart Assoc. 2019, 8, e012741. [] [ CrossRef] Ogiso, M.; Yamaguchi, J.; Otsuki, H.; Arashi, H.; Sekiguchi, H.; Ogawa, H.; Hagiwara, N. Association between Anemia and Mortality in Patients with Acute Coronary Syndrome Treated with Percutaneous Coronary Intervention and Contemporary Lipid-Lowering Therapy. Heart Vessel. 2021, 36, 1626–1634. [] [ CrossRef] Faggioni, M.; Baber, U.; Sartori, S.; Chandrasekhar, J.; Cohen, D.J.; Henry, T.D.; Claessen, B.E.; Dangas, G.D.; Gibson, C.M.; Krucoff, M.W.; et al. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. Circ. Cardiovasc Interv. 2019, 12, e007133. [] [ CrossRef] Yazji, K.; Abdul, F.; Elangovan, S.; Ul Haq, M.Z.; Ossei-Gerning, N.; Morris, K.; Anderson, R.; Kinnaird, T. Baseline Anemia in Patients Undergoing Percutaneous Coronary Intervention after an Acute Coronary Syndrome-A Paradox of High Bleeding Risk, High Ischemic Risk, and Complex Coronary Disease. J. Interv. Cardiol. 2017, 30, 491–499. [] [ CrossRef] Vicente-Ibarra, N.; Marín, F.; Pernías-Escrig, V.; Sandín-Rollán, M.; Núñez-Martínez, L.; Lozano, T.; Macías-Villaniego, M.J.; Carrillo-Alemán, L.; Candela-Sánchez, E.; Guzmán, E.; et al. Impact of Anemia as Risk Factor for Major Bleeding and Mortality in Patients with Acute Coronary Syndrome. Eur. J. Intern Med. 2019, 61, 48–53. [] [ CrossRef] [ PubMed] Lee, G.; Choi, S.; Kim, K.; Yun, J.M.; Son, J.S.; Jeong, S.M.; Kim, S.M.; Park, S.M. Association of Hemoglobin Concentration and Its Change with Cardiovascular and All-Cause Mortality. J. Am. Heart Assoc. 2018, 7, e007723. [] [ CrossRef] Zhang, Z.; Gao, S.; Dong, M.; Luo, J.; Xu, C.; Wen, W.; Huang, Y.; Wu, Y.; Zhou, J.; Yuan, Z. Relationship between Red Blood Cell Indices (MCV, MCH, and MCHC) and Major Adverse Cardiovascular Events in Anemic and Nonanemic Patients with Acute Coronary Syndrome. Dis. Markers 2022, 2022, 2193343. [] [ CrossRef] Huang, Y.L.; Hu, Z.D. Lower Mean Corpuscular Hemoglobin Concentration Is Associated with Poorer Outcomes in Intensive Care Unit Admitted Patients with Acute Myocardial Infarction. Ann. Transl. Med. 2016, 4, 190. [] [ CrossRef] [ PubMed] Ranjith, M.P.; DivyaRaj, R.; Mathew, D.; George, B.; Krishnan, M.N. Mean Platelet Volume and Cardiovascular Outcomes in Acute Myocardial Infarction. Heart Asia 2016, 8, 16–20. [] [ CrossRef] [ PubMed] Ebina, T.; Tochihara, S.; Okazaki, M.; Koike, K.; Tsuto, Y.; Tayama, M.; Takanami, Y.; Hirose, H.; Horii, M.; Okada, K.; et al. Impact of Red Blood Cell Distribution Width and Mean Platelet Volume in Patients with ST-Segment Elevation Myocardial Infarction. Heart Vessel. 2022, 37, 392–399. [] [ CrossRef] Ekmekci, Ö.Ö.; Karaca, G.; Kimiaei, A.; Safaei, S.; Ekmekci, A. Mean Platelet Volume and Its Association with In-Hospital Outcomes in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Cureus 2024, 16, e55606. [] [ CrossRef] [ PubMed] Thygesen, K.; Alpert, J.S.; White, H.D.; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction; Jaffe, A.S.; Apple, F.S.; Galvani, M.; Katus, H.A.; Newby, L.K.; Ravkilde, J.; et al. Universal Definition of Myocardial Infarction. Circulation 2007, 116, 2634–2653. [] [ CrossRef] Stamerra, C.A.; D’Elia, E.; Gori, M.; Roncali, F.; Cereda, A.; Gavazzi, A.; Ferri, C.; Senni, M. Red Cell Distribution Width (RDW) Is Correlated to Time of Oxygen Desaturation < 90% and Length of Sleep Apneas in Patients with Sleep Disorder Breathing (SDB) and Acute Heart Failure with Preserved Ejection Fraction (HFpEF). Front. Cardiovasc. Med. 2023, 10, 1045702. [] [ CrossRef] Carson, J.L.; Brooks, M.M.; Hébert, P.C.; Goodman, S.G.; Bertolet, M.; Glynn, S.A.; Chaitman, B.R.; Simon, T.; Lopes, R.D.; Goldsweig, A.M.; et al. Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia. N. Engl. J. Med. 2023, 389, 2446–2456. [] [ CrossRef] Ducrocq, G.; Gonzalez-Juanatey, J.R.; Puymirat, E.; Lemesle, G.; Cachanado, M.; Durand-Zaleski, I.; Arnaiz, J.A.; Martínez-Sellés, M.; Silvain, J.; Ariza-Solé, A.; et al. Effect of a Restrictive vs. Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients with Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial. JAMA 2021, 325, 552–560. [] [ CrossRef] [ PubMed] Figure 1. Kaplan–Meier estimates of cumulative event probability for 3-point MACE by admission tertiles. ( A) hemoglobin, ( B) erythrocyte count, ( C) MCHC, and ( D) MPV at admission are shown in three groups (low, medium, high). Abbreviations: MACE, major adverse cardiovascular events; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; MPV, mean platelet volume. Figure 1. Kaplan–Meier estimates of cumulative event probability for 3-point MACE by admission tertiles. ( A) hemoglobin, ( B) erythrocyte count, ( C) MCHC, and ( D) MPV at admission are shown in three groups (low, medium, high). Abbreviations: MACE, major adverse cardiovascular events; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; MPV, mean platelet volume. Figure 2. Adjusted hazard ratios of 3-point MACE for hemogram values at admission. ( A) hemoglobin, ( B) erythrocyte count, ( C) hematocrit, ( D) MCH, ( E) MCHC, ( F) MCV, ( G) platelet count, and ( H) MPV. Abbreviations: Hb, hemoglobin; HR, hazard ratio; MACE, major adverse cardiovascular events; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; MPV, mean platelet volume. Figure 2. Adjusted hazard ratios of 3-point MACE for hemogram values at admission. ( A) hemoglobin, ( B) erythrocyte count, ( C) hematocrit, ( D) MCH, ( E) MCHC, ( F) MCV, ( G) platelet count, and ( H) MPV. Abbreviations: Hb, hemoglobin; HR, hazard ratio; MACE, major adverse cardiovascular events; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; MPV, mean platelet volume. Baseline characteristics. Baseline characteristics. Characteristics Overall N = 10,920 1No MACE N = 7480 1MACE N = 3440 1p-Value 2Age (years) ୬୬.୬ ବ୍ଦ ୧୨.୭ ୬୪.୩ ବ୍ଦ ୧୨.୫ ୭୧.୫ ବ୍ଦ ୧୧.୬ <0.001 Sex <0.001 Female 3804 (34.8%) 2492 (33.3%) 1312 (38.1%) Male 7116 (65.2%) 4988 (66.7%) 2128 (61.9%) Height (cm) 170.0 (164.0, 176.0) 171.0 (165.0, 178.0) 170.0 (163.0, 175.0) <0.001 Weight (kg) 79.0 (70.0, 90.0) 80.0 (70.0, 90.0) 77.0 (67.0, 87.0) <0.001 BMI (kg/m 2) 27.0 (24.4, 30.0) 27.1 (24.5, 30.1) 26.7 (24.0, 29.7) <0.001 Hypertension 7889 (72.2%) 5237 (70.0%) 2652 (77.1%) <0.001 Hyperlipidemia 4825 (44.2%) 3240 (43.3%) 1585 (46.1%) 0.007 Diabetes 2712 (24.8%) 1601 (21.4%) 1111 (32.3%) <0.001 COPD 945 (8.7%) 536 (7.2%) 409 (11.9%) <0.001 Atrial fibrillation 1437 (13.2%) 747 (10.0%) 690 (20.1%) <0.001 Asthma 140 (1.3%) 94 (1.3%) 46 (1.3%) 0.728 GFR (CKD-EPI) 73.8 (54.2, 89.7) 76.7 (59.3, 92.3) 58.8 (40.9, 79.1) <0.001 Type of MI <0.001 STEMI 4107 (37.6%) 2900 (38.8%) 1207 (35.1%) NSTEMI 6808 (62.3%) 4575 (61.2%) 2233 (64.9%) 1 Mean ± SD; Median (Q1, Q3); n (%), 2 Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test. Abbreviations: MACE, major adverse cardiovascular event. Multivariable Cox regression analysis of MACE with hematological marker tertiles at admission and discharge. Multivariable Cox regression analysis of MACE with hematological marker tertiles at admission and discharge. Characteristic HR 95% CI p-Value FDR-Adjusted p-Value Hemoglobin tertiles (admission) High 1.11 1.02, 1.22 0.023 0.061 Low 1.19 1.09, 1.29 <0.001 <0.001 Hemoglobin tertiles (discharge) High 0.91 0.83, 1.00 0.055 0.126 Low 1.27 1.18, 1.38 <0.001 <0.001 Erythrocytes tertiles (admission) High 1.08 0.98, 1.18 0.106 0.170 Low 1.12 1.03, 1.22 0.006 0.032 Erythrocytes tertiles (discharge) High 0.99 0.90, 1.08 0.755 0.755 Low 1.24 1.14, 1.34 <0.001 <0.001 Hematocrit tertiles (admission) High 1.09 1.00, 1.19 0.060 0.107 Low 1.11 1.02, 1.20 0.017 0.054 Hematocrit tertiles (discharge) High 0.98 0.89, 1.07 0.608 0.695 Low 1.27 1.18, 1.38 <0.001 0.045 MCH tertiles (admission) High 0.99 0.91, 1.08 0.785 0.966 Low 1.09 1.01, 1.18 0.034 0.072 MCH tertiles (discharge) High 0.95 0.87, 1.03 0.227 0.330 Low 1.04 0.96, 1.13 0.323 0.431 MCHC tertiles (admission) High 0.98 0.90, 1.08 0.725 0.966 Low 1.17 1.08, 1.27 <0.001 <0.001 MCHC tertiles (discharge) High 0.92 0.84, 1.01 0.067 0.134 Low 1.14 1.05, 1.23 0.001 0.003 MCV tertiles (admission) High 1.00 0.92, 1.09 0.986 0.986 Low 1.00 0.92, 1.08 0.971 0.986 MCV tertiles (discharge) High 1.04 0.96, 1.13 0.359 0.442 Low 1.02 0.94, 1.10 0.709 0.755 Platelet count tertiles (admission) High 1.11 1.02, 1.21 0.012 0.048 Low 1.00 0.92, 1.09 0.920 0.986 Platelet count tertiles (discharge) High 1.15 1.06, 1.24 0.001 0.003 Low 1.06 0.98, 1.16 0.145 0.232 MPV tertiles (admission) High 1.09 1.01, 1.18 0.036 0.072 Low 1.03 0.95, 1.12 0.449 0.653 MPV tertiles (discharge) High 1.19 1.10, 1.29 <0.001 <0.001 Low 1.07 0.98, 1.17 0.108 0.192 The middle tertile served as the reference category for all hematological parameters and is therefore not displayed. Adjusted p-values were calculated using the Benjamini–Hochberg false-discovery-rate procedure. Abbreviations: CI, confidence interval; FDR, false discovery rate; HR, hazard ratio; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; MPV, mean platelet volume. Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Share and Cite MDPI and ACS Style Strohhofer, C.; Aziz, F.; Kainz, A.; Berghold, A.; Verheyen, N.; Bugger, H.; Hatzl, S.; Planka, R.; von Lewinski, F.; Gollmer, J.; et al. Erythrocyte and Platelet Indices at Admission and Discharge Stratify Long-Term Cardiovascular Risk After Invasive Treatment of Myocardial Infarction. J. Clin. Med. 2026, 15, 4455. https://doi.org/10.3390/jcm15124455 AMA Style Strohhofer C, Aziz F, Kainz A, Berghold A, Verheyen N, Bugger H, Hatzl S, Planka R, von Lewinski F, Gollmer J, et al. Erythrocyte and Platelet Indices at Admission and Discharge Stratify Long-Term Cardiovascular Risk After Invasive Treatment of Myocardial Infarction. Journal of Clinical Medicine. 2026; 15(12):4455. https://doi.org/10.3390/jcm15124455 Chicago/Turabian Style Strohhofer, Christoph, Faisal Aziz, Andreas Kainz, Andrea Berghold, Nicolas Verheyen, Heiko Bugger, Stefan Hatzl, Raffaela Planka, Friederike von Lewinski, Johannes Gollmer, and et al. 2026. "Erythrocyte and Platelet Indices at Admission and Discharge Stratify Long-Term Cardiovascular Risk After Invasive Treatment of Myocardial Infarction" Journal of Clinical Medicine 15, no. 12: 4455. https://doi.org/10.3390/jcm15124455 APA Style Strohhofer, C., Aziz, F., Kainz, A., Berghold, A., Verheyen, N., Bugger, H., Hatzl, S., Planka, R., von Lewinski, F., Gollmer, J., Ablasser, K., Vosko, I., Sacherer, M., Toth, G. G., Kolesnik, E., Zirlik, A., Sourij, H., & von Lewinski, D. (2026). Erythrocyte and Platelet Indices at Admission and Discharge Stratify Long-Term Cardiovascular Risk After Invasive Treatment of Myocardial Infarction. Journal of Clinical Medicine, 15(12), 4455. https://doi.org/10.3390/jcm15124455 Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details . Article Metrics Article metric data becomes available approximately 24 hours after publication online.
